Endomedix has developed a platform technology with 4 major potential applications. The Company is developing its first product, an absorbable sugrical hemostat for brain and spinal surgery. The core development for this product has been completed. The hemostat does not swell in use and has the most rapid action of any absorbable hemostat. The hemostat has 5 mechanisms of action, 4 of which are subject to patent application. The technology is based on polysaccharides and is protected by 8 issued patents and two pending patent applications. The starting materials of the product have a longhistory of use in FDA-regulated products.,Endomedix has developed a platform technology with 4 major potential applications. The Company is developing its first product, an absorbable sugrical hemostat for brain and spinal surgery. The core development for this product has been completed. The hemostat does not swell in use and has the most rapid action of any absorbable hemostat. The hemostat has 5 mechanisms of action, 4 of which are subject to patent application. The technology is based on polysaccharides and is protected by 8 issued patents and two pending patent applications. The starting materials of the product have a longhistory of use in FDA-regulated products.

打呼噜，又称为鼾症，大多数人认为这是司空见惯的，非但对此不以为然，还有人把打呼噜看成睡得香的表现。其实打呼噜是导致高血压及心脑血管栓塞的危险因素之一，具有潜在危害性。 2016年，全国打鼾人员总数为6亿多人，男女老少普遍存在。因此，高端智能云呼吸机拥有几百亿的巨大市场，而且，目前市场上还没有同类产品和服务，为全球首创。 目前，市场上没有一个专业的人工智能云平台提供治疗打鼾的云上和线下一站式系统服务；这是一个有巨大需求的市场空白区。经过了多年的线下实践活动，对市场前景、发展机会、竞争优势、法律法规等已经做了充分的调研。团队成员在医疗、融资、运营管理、网络方面已有多个成功案例，既有海外背景又有国内实战经验，在执行力上有充分保障。,打呼噜，又称为鼾症，大多数人认为这是司空见惯的，非但对此不以为然，还有人把打呼噜看成睡得香的表现。其实打呼噜是导致高血压及心脑血管栓塞的危险因素之一，具有潜在危害性。 2016年，全国打鼾人员总数为6亿多人，男女老少普遍存在。因此，高端智能云呼吸机拥有几百亿的巨大市场，而且，目前市场上还没有同类产品和服务，为全球首创。 目前，市场上没有一个专业的人工智能云平台提供治疗打鼾的云上和线下一站式系统服务；这是一个有巨大需求的市场空白区。经过了多年的线下实践活动，对市场前景、发展机会、竞争优势、法律法规等已经做了充分的调研。团队成员在医疗、融资、运营管理、网络方面已有多个成功案例，既有海外背景又有国内实战经验，在执行力上有充分保障。

1.该项目是在美国Tesla(特斯拉)汽车的变频电机调速驱动装置的基础上发明创新的。 2.它解决了美国Tesla（特斯拉）电动汽车至今还没有解决的变速器问题：Tesla（特斯拉）的第一个车型Roadster的最初设计是180kW电机+2档变速箱，后来由于变速箱质量的问题，被迫采用了第二种方案，取消了变速箱。 3.本项目是利用变极变频电动车驱动装置中的电机变极功能，取代当今世界电动汽车至今还没有完善解决的复杂笨重的机械变速箱装置，而且它能自动调节变极速度骤然变化，使车子行驶平稳舒适。它不仅仅解决特斯拉尚存机械变速箱的问题；也完成了中国863提出电动车驱动装置的重要课题；它将比特斯拉驱动装置在低速路段的效率上升30%，高速路段效率上升15%，巡航公里数增加20%，装置价格下降10%。 因此说，它的诞生将是汽车在经有一百多年历史的机械变速箱上的一场革命，是电动汽车在全球范围内的一项重大创举。 4．由于该项目性价比高，运行稳定，重量轻，免维修，它不仅仅将取代世界领先的美国Tesla model 3 的驱动系统，而且将取代今天占领中国电动车90%市场的永磁电动车驱动系统而成为中国每年的一万亿元的电动车驱动装置市场的垄断者，而将成为未来五万亿元的世界市场中一个不可忽视的竞争者。 5.本项目曾获得科学技术部与教育部联合举办“春晖杯”奖。,1.该项目是在美国Tesla(特斯拉)汽车的变频电机调速驱动装置的基础上发明创新的。 2.它解决了美国Tesla（特斯拉）电动汽车至今还没有解决的变速器问题：Tesla（特斯拉）的第一个车型Roadster的最初设计是180kW电机+2档变速箱，后来由于变速箱质量的问题，被迫采用了第二种方案，取消了变速箱。 3.本项目是利用变极变频电动车驱动装置中的电机变极功能，取代当今世界电动汽车至今还没有完善解决的复杂笨重的机械变速箱装置，而且它能自动调节变极速度骤然变化，使车子行驶平稳舒适。它不仅仅解决特斯拉尚存机械变速箱的问题；也完成了中国863提出电动车驱动装置的重要课题；它将比特斯拉驱动装置在低速路段的效率上升30%，高速路段效率上升15%，巡航公里数增加20%，装置价格下降10%。 因此说，它的诞生将是汽车在经有一百多年历史的机械变速箱上的一场革命，是电动汽车在全球范围内的一项重大创举。 4．由于该项目性价比高，运行稳定，重量轻，免维修，它不仅仅将取代世界领先的美国Tesla model 3 的驱动系统，而且将取代今天占领中国电动车90%市场的永磁电动车驱动系统而成为中国每年的一万亿元的电动车驱动装置市场的垄断者，而将成为未来五万亿元的世界市场中一个不可忽视的竞争者。 5.本项目曾获得科学技术部与教育部联合举办“春晖杯”奖。

• We propose to bring to market a ground-breaking treatment to retard the onset of or prevent Alzheimer’s disease (AD). • The concept is based on original new observations that have emerged from our studies showing that there is age-related damage to the tiny capillary blood vessels (called the blood brain barrier or BBB), which supply the brain, and that the major genetic and non-genetic risk factors for AD greatly worsen this damage. BBB damage is a major pathology in symptomatic and pre-symptomatic AD. • BBB leakage is found to occur in middle age in humans and pre-clinical models. This BBB damage primarily affects the brain in the hippocampus, which is important for memory, and is particularly affected in AD. • These observations are consistent with the strongly supported concept that AD is a disease of the capillary blood supply to the brain, particularly in its early stages. • Our studies identify a fundamental mechanism underlying this damage, which can be targeted and healed with a known drug that is licensed for a completely different purpose. • The value in the concept both therapeutically and financially can be developed by targeting the known drug for an Orphan indication involving damage to the BBB, which would provide exclusivity for a period of time. • In parallel we will develop a better targeted new drug(s). • Additionally we will develop biomarkers for BBB damage that can be used to indicate the use of our drug through the prediction of AD risk, and monitor its efficacy. • We are seeking foresighted investors with an interest in the early-stage development of high-impact biopharmaceutical products in order to advance our concept. Funds secured will be used to advance the company’s ~£6.0-7.0 million Discovery and Development, and Preclinical program for AD risk modification, with additional ~£3.0-4.0 million funding for phase 1 human studies. • There are caveats to the Company valuation because of the existence of a known drug that can heal the BBB. - Repurposing might be challenging as the acute clinical trials have shown no improvement in cognition with the known drug, so that a longer expensive, trial is needed, but the length of this trial may well be mitigated by the use of our biomarkers. - The valuation is also complicated by the commercial impact of generic pricing following expiration of the know drugs patents which may limit pricing and reduce the attractiveness to a large Pharma partner. • Importantly, our strategy is anticipated to provide a preventative treatment for this devastating disease for which there is no treatment, and where there have been multiple drug development failures. This, irrespective of remuneration would have a huge impact by improving human suffering. • We suggest the conservative valuation of $US 20-30 million upfront at the end of the pre-clinical stage and $US 60-90 million deal total deal value. • This would give a more than 5 to 8 fold return on investment of £11.0 million. • However, the anticipated “frenzy” of demand that might well be generated by rapidly bringing to market a preventative drug treatment strategy for AD very likely trigger very substantial sales, with greatly enhanced Company valuation.,• We propose to bring to market a ground-breaking treatment to retard the onset of or prevent Alzheimer’s disease (AD). • The concept is based on original new observations that have emerged from our studies showing that there is age-related damage to the tiny capillary blood vessels (called the blood brain barrier or BBB), which supply the brain, and that the major genetic and non-genetic risk factors for AD greatly worsen this damage. BBB damage is a major pathology in symptomatic and pre-symptomatic AD. • BBB leakage is found to occur in middle age in humans and pre-clinical models. This BBB damage primarily affects the brain in the hippocampus, which is important for memory, and is particularly affected in AD. • These observations are consistent with the strongly supported concept that AD is a disease of the capillary blood supply to the brain, particularly in its early stages. • Our studies identify a fundamental mechanism underlying this damage, which can be targeted and healed with a known drug that is licensed for a completely different purpose. • The value in the concept both therapeutically and financially can be developed by targeting the known drug for an Orphan indication involving damage to the BBB, which would provide exclusivity for a period of time. • In parallel we will develop a better targeted new drug(s). • Additionally we will develop biomarkers for BBB damage that can be used to indicate the use of our drug through the prediction of AD risk, and monitor its efficacy. • We are seeking foresighted investors with an interest in the early-stage development of high-impact biopharmaceutical products in order to advance our concept. Funds secured will be used to advance the company’s ~£6.0-7.0 million Discovery and Development, and Preclinical program for AD risk modification, with additional ~£3.0-4.0 million funding for phase 1 human studies. • There are caveats to the Company valuation because of the existence of a known drug that can heal the BBB. - Repurposing might be challenging as the acute clinical trials have shown no improvement in cognition with the known drug, so that a longer expensive, trial is needed, but the length of this trial may well be mitigated by the use of our biomarkers. - The valuation is also complicated by the commercial impact of generic pricing following expiration of the know drugs patents which may limit pricing and reduce the attractiveness to a large Pharma partner. • Importantly, our strategy is anticipated to provide a preventative treatment for this devastating disease for which there is no treatment, and where there have been multiple drug development failures. This, irrespective of remuneration would have a huge impact by improving human suffering. • We suggest the conservative valuation of $US 20-30 million upfront at the end of the pre-clinical stage and $US 60-90 million deal total deal value. • This would give a more than 5 to 8 fold return on investment of £11.0 million. • However, the anticipated “frenzy” of demand that might well be generated by rapidly bringing to market a preventative drug treatment strategy for AD very likely trigger very substantial sales, with greatly enhanced Company valuation.

Back pain is a global epidemic without a viable solution, but the cause of pain is surprisingly simple. Through an X-ray guided needle, we re-establish fluid exchange through spirals of suture between the painful disc and body circulation for instant pain relief and MRI improvement, indicating disc regeneration for long-term pain relief.,Back pain is a global epidemic without a viable solution, but the cause of pain is surprisingly simple. Through an X-ray guided needle, we re-establish fluid exchange through spirals of suture between the painful disc and body circulation for instant pain relief and MRI improvement, indicating disc regeneration for long-term pain relief.

曲贝替定是种从海洋生物中提取出的抗癌药物，用于晚期软组织肉瘤的治疗。该药物结构复杂，价格极其昂贵，国内还没有仿制药进行申报。我公司与制药公司进行合作，开发该药物的合成工艺并进行申报，希望能够在国内开发出仿制药并成功上市。,曲贝替定是种从海洋生物中提取出的抗癌药物，用于晚期软组织肉瘤的治疗。该药物结构复杂，价格极其昂贵，国内还没有仿制药进行申报。我公司与制药公司进行合作，开发该药物的合成工艺并进行申报，希望能够在国内开发出仿制药并成功上市。